Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 9, 2005 - Issue 1
Submit an article Journal homepage
93
Views
21
CrossRef citations to date
0
Altmetric
Review

Novel strategies for prevention and treatment of influenza

Ruth Kandel Harvard University School of Medicine, Hebrew Rehabilitation Center for Aged Internal Medicine/Geriatrics, 1200 Centre Street, Boston, MA 02131-1097, USA
&
Kevan L Hartshorn Boston University School of Medicine, Section of Hematology/Oncology, USA
Pages 1-22 | Published online: 22 Apr 2005

Bibliography

  • MORENS D: Influenza-related mortality: considerations for practice and public health. IA/VIA (2003) 289:227–229.
  • NICHOL K, LINDA, MARGOLIS K et al.: The effectiveness of vaccination against influenza in healthy working adults. N. Eng. J. Med. (1995) 333:889–893.
  • IZURIETA HS, THOMPSON WW, KRAMARZ P et al.: Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl. J. Med. (2000) 342:232–239.
  • STEVENS J, CORPER A, BASLER C, TAUBENBERGER J, PALESE P, WILSON I: Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Sciencexpress (2004) 1093373.
  • WEBBY RJ, WEBSTER RG: Are we ready for pandemic influenza? Science (2003) 302:1519–1522.
  • GOTO H, KAWASAKI Y: A novel mechanism for acquisition of virulence by a human influenza A virus. Proc. Nati Acad. Sci. USA (1998) 95:10224–10228.
  • STEINHAUER D: Role of hemagglutinin cleavage for the pathogenicity of influenza virus. Virology (1999) 258:1–20.
  • SAKAGUCHI T, TU Q, PINTO L, LAMB R: The active oligomeric state of the minimalistic influenza virus M2 ion channel is a tetramer. Proc. Natl. Acad. Sci. USA (1997) 94:5000–5005.
  • GRAHAM M, BRACIALE T: Resistance to recovery from lethal influenza viral infection in B lymphocyte deficient mice. I Exp. Med. (1997) 186:2063–2068.
  • VARGHESE J, LAVER W, COLMAN P: Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution. Nature (1983) 303:35–40.
  • ITZSTEIN MV, WU W, KOK G et a/.: Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature (1993) 363:418–423.
  • LIU C, AIR G: Selection and characterization of a neuraminidase minus mutant of influenza virus and its rescue by cloned neuraminidase genes. Virology (1993) 194:403–407.
  • LAMB R, KRUG R: Orthomyxoviridae the viruses and their replication. In: Fields Virology Fields B, Knipe D, Hawley R (Eds.), Lippincott-Raven, Philadelphia (1996):1353–1396.
  • VOORDOUW BC, LINDEN PD, SIMONIAN S, LEI JV, STURKENBOOM MC, STRICKER BH: Influenza vaccination in community-dwelling elderly. Arch. Intern. Med. (2003) 163:1089–1094.
  • NICHOL KL, BAKEN L, NELSON A: Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann. Intern. Med. (1999) 130:397–403.
  • CHRISTENSON B, LUNDBERGH P, HEDLUND J, ORTQVIST A: Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. Lancet (2001) 357:1008–1011.
  • BRIDGES CB, HARPER SA, FUKUDA K: Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. (2003) 52:1–36.
  • NICHOL KL, NORDIN J, MULLOOLY J, LASK R, FILLBRANDT K, IWANE M: Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl. Med. (2003) 348:1322–1332.
  • MADJID M, NAGHAVI M, LITOVSKY S, CASSCELLS W: Influenza and cardiovascular disease a new opportunity for prevention and the need for further studies. Circulation (2003) 108:2730–2736.
  • NAGHAVI M, WYDE P, LITOVSKY S: Influenza infection exerts prominent inflammatory and thrombotic effects on the atherosclerotic plaques of apolipoprotein E-deficient mice. Circulation (2003) 107.
  • BOUWMAN JJ, VISSEREN FL, BOSCH MC et al.: Procoagulant and inflammatory response of virus-infected monocytes. Eur. Clin. Invest. (2002) 32:759–766.
  • BRIDGES CB, KUEHNERT MJ, HALL CB: Transmission of influenza: implications for control in health care settings. CID 2003;37.
  • BRATZLER DW, HOUCK PM, JIANG H et al.: Failure to vaccinate Medicare inpatients: a missed opportunity. Arch. Intern. Med. (2002) 162:2349–2356.
  • POTTER J, STOTT D, ROBERTS M et al.: Influenza vaccination of health care workers in long term care hospitals reduces the mortality of elderly patients. J. Infect. Dis. (1997) 175:1–6.
  • CARMAN W, ELDER A, WALLACE L et al.: Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled study. Lancet (2000)355:93–97.
  • NICHOLSON KG, WOOD JM, ZAMBON M: Influenza. Lancet (2003) 362:1733–1745.
  • LINTON PJ, DORSHKIND K: Age-related changes in lymphocyte development and function. Nat. Immun. (2004) 5:133–139.
  • DENG Y, JING Y, CAMPBELL AE, GRAVENSTEIN S: Age-related impaired Type 1 T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly. J. Immunol (2004) 172:3437–3446.
  • GARCIA GG, MILLER RA: Single-cell analyses reveal two defects in peptide-specific activation of naive T cells from aged mice. ./. Immunol (2001) 166:3151–3157.
  • GARCIA GG, MILLER RA: Age-dependent defects in TCR-triggered cytoskeletal rearrangement in CD4+ T cells. .1 Immunol (2002) 169:5021–5027.
  • PLACKETT TP, BOEHMER ED, FAUNCE DE, KOVACS EJ: Aging and innate immune cells. J. Leukoc. Biol. (2004) 76:291–299.
  • BOEHMER ED, GORAL J, FAUNCE DE, KOVACS EJ: Age-dependent decrease in Toll-like receptor 4-mediated proinflammatory cytokine production and mitogen-activated protein kinase expression. J. Leukoc. Biol. (2004) 75:342–349.
  • RENSHAW M, ROCKWELL J, ENGLEMAN C, GEWIRTZ A, KATZ J, SAMBHARA S: Cutting edge: impaired Toll-like receptor expression and function in aging. J. Immunol (2002) 169:4697–4701.
  • KANDEL R: Neuraminidase inhibitors for the treatment and prevention of influenza. Clinical Geriatrics (2002) 10:57–65.
  • GUBAREVA LV, KAISER L, HAYDEN FG: Influenza virus neuraminidase inhibitors. Lancet (2000) 355:827–835.
  • BRIDGES C, WINQUIST A, FUKUDA K, COX N: Prevention and control of influenza: recommendations of the advisory committee on immunization practices (ACIP). MMWR (2000) 49:1–28.
  • COOPER NJ, SUTTON AJ, ABRAMS KR, WAILOO A, TURNER DA, NICHOLSON KG: Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BE Med. J. (2003) 326:1235–1240.
  • NICHOLSON K, AOKI F, OSTERHAUS A et al: Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Lancet (2000) 355:1845–1850.
  • ROTHBERG MB, BELLANTONIO S, ROSE DN: Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy. Ann. Intern. Med. (2003) 139:321–329.
  • TREANOR J, HAYDEN F, VROOMAN Pet al.: Efficacy and Safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza. JAMA (2000) 283:1016–1024.
  • MONTO A, FLEMING D, HENRY D et al.: Efficacy and safety of the neuraminidase inhibitor zanamavir in the treatment of influenza A and B virus infections. J. Infect. Dis. (1999) 180:254–261.
  • MONTO A, ROBINSON D, HERLOCHER M, HINSON J, ELLIOT M, CRISP A: Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. N. Engl. J. Med. (1999) 341:1336–1343.
  • MIST: Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet (1998) 352:1877–1881.
  • LALEZARI J, CAMPION K, KEENE O, SILAGY C: Zanamivir for treatment of influenza A and B in high-risk patients. Arch. Int. Med. (2001) 161:212–217.
  • BOIVIN G, GOYETTE N, HARDY I et al.: Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults. J. Infect. Dis. (2000) 181:1471–1474.
  • HAYDEN F, ATMAR R, SCHILLING M et al: Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl. I Med. (1999) 341:1336–1343.
  • HAYDEN FG, GUBAREVA LV, MONTO AS et al: Inhaled zanamivir for the prevention of inluenza in families. Znamivir Family Study Group. N. Engl. J. Med. (2000) 343:1282–1289.
  • HAYDEN FG, BELSHE R, VILLANUEVA C et al.: Management of influenza in housholds: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. JIB (2004) 189:440–449.
  • WELLIVER R, MONTO A, CAREWICZ O et al: Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. "AMA (2001) 285:748–754.
  • PETERS P, GRAVENSTEIN S, NORWOOD P: Long term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail elderly population. J. Am. Ceriat. Soc. (2001) 49:1025–1031.
  • MCKIMM-BRESCHKIN JL: Resistance of influenza viruses to neuraminidase inhibitors - a review Antiviral Res. (2000) 47:1–17.
  • GUBAREVA L, MATROSOVICH M, BRENNER M, BETHELL R, WEBSTER R: Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. (1998) 178:1257–1262.
  • GUBAREVA LV, KAISER L, MATROSOVICH MN et al: Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis. (2001) 183:523–531.
  • HARPER SA, FUKUDA K, UYEKI TM, COX NJ, BRIDGES CB: Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. (2004) 53:1–40.
  • WILLIAMSON J, PEGRAM P: Respiratorydistress associated with zanamivir. N Engl." Med. (2000) 342:661–662.
  • MURPHY KR, EIVINDSON A, PAUKSENS K et al: Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease. A double-blind, randomized, placebo-controlled, multicentre study. Clia Drug Invest. (2000) 20:337–349.
  • DIGGORY P, FERNANDEZ C, HUMPHREY A et al: Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial. Br. Med. J. (2001) 322:577–579.
  • LEE C, LOEB M, PHILLIPS A et al: Zanamivir use during transmission of amantadine-resistant influenza A in a nursing home. Infect. Control Hosp. Epidemiol (2000) 21:700–704.
  • KASSCHAU M, BARABINO G, BRIDGES K, GOLAN D: Adhesion of sickle neutrophils and erythrocytes to fibronectin. Blood (1996) 87:771–780.
  • AHFS: Rimantadine Hydrochloride. AHFS Drug Information 1998.
  • SEARS S, CLEMENTS M: Protective efficacy of low-dose amantadine in adults challenged with wild-type influenza A virus. Antimicrob. Agents Chemother. (1987) 31:1470–1473.
  • KEYSER L, KARL M, NAFZIGER A, BERTINO J: Comparison of central nervous system adverse effects of amantadine and rimantadine used a sequential prophylaxis of influenza A in elderly nursing home patients. Arch. Intern. Med. (2000) 160:1485–1488.
  • BELSHE R, SMITH M, HALL C, BETTS R, HAY A: Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J. Vim]. (1988) 62:1508–1512.
  • ENGLUND J, CHAMPLIN R, WYDE P et al.: Common emergence of amantadine and rimantidine resistant influenza A viruses in symptomatic immunocompromised patients. Clia Infect. Dir. (1998) 26:1418–1424.
  • HAYDEN F, BELSHE R, CLOVER R, HAY A, OAKES M, SOO W: Emergence and apparent transmission of rimantadine resistant influenza A virus in families. N Engl. I Med. (1989) 321:1696–1702.
  • KRAMARZ P, DESTEFANO F, GARGIULLO PM et al: Does influenza vaccination prevent asthma exacerbations in children?' Pediatr: (2001) 138:306–310.
  • NEUZIL KM: Influenza vaccine in childrenwith asthma: Why no progress? Pediatr: (2001) 138:301–303.
  • ERHART LM, RANGEL MC, LU P, SINGLETON JA: Prevalence and characteristics of children at increased risk for complications from influenza, United States, 2000.1 Pediatr. (2004) 144:191–195.
  • NEUZIL KM, MELLEN BG, WRIGHT PF, MITCHEL EF, GRIFFIN MR: The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl. J. Med. (2000) 342:225–231.
  • PRINCIPI N, ESPOSITO S, MARCHISIO P, GASPARINI R, CROVARI P: Socioeconomic impact of influenza on healthy children and their families. Fed. Inf. Dis. I (2003) 22:S207–S210.
  • REICHERT TA, SUGAYA N, FEDSON DS, GLEZEN P, SIMONSEN L, TASHIRO M: The Japanese experience with vaccinating schoolchildren against influenza. N Engl. J. Med. (2001) 344:889–896.
  • NICHOL KL: Live attenuated influenza virus vaccines: new options for the prevention of influenza. Vaccine (2001) 19:4373–4377.
  • BELSHE RB, MENDELMAN PM, TREANOR J et al.: The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl. I Med. (1998) 338:1405–1412.
  • BELSHE RB, GRUBER WC, WILLIAM C et al.: Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intransal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. .1 Pediatr. (2000) 136:168–175.
  • ARULANANDAM B, MITTLER J, LEE W, O'TOOLE M, METZGER D: Neonatal administration of IL-12 enhances the protective efficacy of antiviral vaccines. J. ImmunoL (2000) 164:3698–3704.
  • PEIRIS JS, YU W, LEUNG C et al.: Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet (2004) 363:617–619.
  • YUEN KY, CHAN PKS, PEIRIS M et al.:Clinical features and rapid viral diagnosis of human disease associated with avian influenza a H5N1 virus. Lancet (1998) 351:467–471.
  • HIEN T, LIEM N, DUNG N et al: Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl. I Med. (2004) 350:1179–1188.
  • CHEUNG C, POON L, LAU A et al.: Induction of pro-inflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet (2002) 360: 1831-1837.
  • KOOPMANS M, WILBRINK B, CONYN M et al.: Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet (2004) 363:587–593.
  • STEPHENSON I, NICHOLSON K, GLUCK R et al.: Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: Phase I randomised trial. Lancet (2003) 362: 1959-1966.
  • MATROSOVICH MN, KRAUSS S, WEBSTER RG: H9N2 influenza A viruses from poultry in Asia have human virus-like receptor specificity. Virology (2001) 281:156–162.
  • GAMBLIN S, HAIRE L, RUSSELL R et al.: The structure and receptor-binding properties of the 1918 influenza hemagglutinin. Sciencexpress (2004) 1093155:1–6.
  • TUMPEY T, GARCIA-SASTRE A, TAUBENBERGER J, PALESE P, SWAYNE D: Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus. Proc. Natl. Acad. ScL U.S.A. (2004) 101:3166–3171.
  • LONGINI I, HALLORAN M, NIZAM A, YANG Y: Containing pandemic influenza with antiviral agents. Am. J. Epidennol. (2004) 159:623–633.
  • GOVORKOVA E, LENEVA I, GOLOUBEVA O, BUSH K, WEBSTER R: Comparison of efficacies of RWJ-270201, Zanamivir, and Oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicro. Ag. Chemo. (2001) 45:2723–2732.
  • SPELLBERG B, EDWARDS JE: Type 1/Type2 immunity in infectious diseases. Clin. Infect. Dis. (2001) 32:76–102.
  • ONEILL E, KRAUSS S, RIBERDY J, WEBSTER R, WOODLAND D: Heterologous protection against lethal A/HongKong/156/97 (H5N1) influenza virus infection of C57BL/6 mice. J. Gen. Viral (2000) 81:2689–2696.
  • JUSTEWICZ D, POHLMAN E, SHEEHY M, WEBSTER R: Particle-mediated epidermal delivery of DNA and inactivated virus. In: Options for the control of lidluenza III Brown L, Hampson A, Webster R (Eds.), Elsevier, Amsterdam (1996).
  • DONNELLY J, FRIEDMAN A, MARTINEZ A et al: Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift. Nat. Med. (1995) 1:583–587.
  • SHEDLOCK D, WEINER D: DNA vaccination: antigen presentation and the induction of immunity. I Leuk. Biol. (2000) 68:793–806.
  • JOHNSON P, CONWAY M, DALY J, NICOLSON C, ROBERTSON J, MILLS K: Plasmid DNA encoding influenza virus haemagglutinin induces Thl cells and protection against respiratory infection despite its limited ability to generate antibody responses. J. Gen. Viral (2000) 81:1737–1745.
  • FU T, FRIEDMAN A, ULMER J, LIU M, DONNELLY J: Protective cellular immunity: cytotoxic T-lymphocyte responses against dominant and recessive epitopes of influenza virus nucleoprotein induced by DNA immunization. I Viral (1997) 71:2715–2721.
  • SASAKI S, TAKESHITA F, OIKAWA T et al.: Improvement of DNA vaccine immunogenicity by a dual antigen expression system. Biochem. Biophys. Res. Commun. (2004) 315:38–43.
  • KENT S, ZHAO A, BESTS, CHANDLER J, BOYLE D, RAMSHAW I: Enhanced T cell immunogenicity and protective efficacy of a human immunodeficiency Type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowl pox virus. J. Viral (1998) 72:10180–10188.
  • CHATTERGOON MA, SAULINO V, SHAMES JP, STEIN J, MONTANER LJ, WEINER DB: Co-immunization with plasmid IL-12 generates a strong T-cell memory response in mice. Vaccine (2004) 22:1744–50.
  • BRIGHT R, ROSS T, SUBBARAO K, ROBINSON H, KATZ J: Impact of glycosylation on the immunogenicity of a DNA-based influenza H5 HA vaccine. Virology(2003) 308:270–278.
  • KODIHALLI S, GOTO H, KOBASA DL, KRAUSS S, KAWAOKA Y, WEBSTER RG: DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice. J. Viral (1999) 73:2094–2098.
  • TREANOR J, WILKINSON B, MASSEOUD F et al.: Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine (2001) 19: 1732-1737.
  • NICHOLSON KG, COLEGATE AE, PODDA A et al: Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet (2001) 357: 1937-1943.
  • LU X, CLEMENTS JD, KATZ JM: Mutant Escherichia coli heat-labile enterotoxin FLT(R192G)1 enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine. Vaccine (2002) 70:1019–1029.
  • JONES T, ALLARD F, CYR S et al: A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity. Vaccine (2003) 21:3706–3712.
  • PALESE P, GARCIA-SASTRE A: Influenza vaccines: present and future. Clin. Invest. (2002) 110:9–13.
  • NGUYEN H, MOLDOVEANU Z, NOVAK M et al: Heterosubtypic immunity to lethal influenza A virus infection is associated with virus specific CD8+ cytotoxic T lymphocyte responses induced in mucosa-associated tissue. Virology (1999) 254:50–60.
  • NEIRYNCK S, DER00 T, SAELENS X, VANLANDSCHOOT P, JOU WM, FIERS W: A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. (1999) 5:1157–1163.
  • NEUMANN G, WATANABE T, ITO H et al.: Generation of influenza A viruses entirely from cloned cDNAs. Five. Nati Acad. Sci. USA (1999) 96:9345–9350.
  • WEBBY RJ, PEREZ DR, COLEMAN JS et al: Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet (2004) 363:1099–1103.
  • SUBBARAO K, CHEN H, SWAYNE D et al.: Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology (2003) 305:192–200.
  • OZAKI H, GOVORKOVA E, LI C, XIONG X, WEBSTER R, WEBBY R: Generation of high-yielding influenza A viruses in African great monkey kidney (Vero) cells by reverse genetics. J. Virol. (2004) 78:1851–1857.
  • PARKIN N, CHIU P, COELINGH K: Genetically engineered live attenuated influenza A virus vaccine candidates. Virol. (1997) 71:2772–2778.
  • HERLOCHER M, TRUSCON R, FENTON R et al: Assessment of development of resistance to antivirals in the ferret model of influenza virus infection. J. int: Dis. (2003) 188:1355–1361.
  • MITNAUL LJ, MATROSOVICH MN, CASTRUCCI MR et al: Balanced hemagglutinin and neuraminidase activities are critical for efficient replication of influenza a virus. J. Virol. (2000) 74:6015–6020.
  • MCKIMM-BRESCHKIN J, BLICK T, SAHASRABUDHE A et al.: Influenza virus variants with decreased sensitivity to 4-amino- and 4-guanidino-Neu5Ac2en. In: Options for the control of influenza III. Brown L, Hampson A, Webster R (Eds.), Elsevier, Amsterdam (1996).
  • BAIGENT SJ, MCCAULEY JW: Glycosylation of haemagglutinin and stalk-length of neuraminidase combine to regulate the growth of avian influenza viruses in tissue culture. Virus Res. (2001) 79:177–185.
  • MATROSOVICH M, MATROSOVICH T, CARR J, ROBERTS NA, KLENK H: Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. Virol. (2003) 77:8418–8425.
  • GUBAREVA L, WEBSTER R, HAYDEN F: Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrobial Agents Cherno. (2001) 45:3403–3408.
  • MASUDA T, YOSHIDA S, ARAI M, KANEKO S, YAMASHITA M, HONDA T: Synthesis and anti-influenza evaluation of plyvalent sialidase inhibitors bearing 4-Guanidino-Neu5Ac2en derivatives. Chem. Pharm. Bull. (2003) 51:1386–1398.
  • WATSON K, CAMERON R, FENTON R et al.: Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase. Bioorg. Med. Chem. Lett. (2004) 14:1589–1592.
  • DAIGNEAULT DE, HARTSHORN KL, LIOU LS et al.: Influenza A virus binding to human neutrophils and cross-linking requirements for activation. Blood (1992) 80:3227–3234.
  • HARTSHORN KU, LIOU LS, WHITE MR, KAZHDAN MM, TAUBER JL: Neutrophil deactivation by influenza A virus: Role of hemagglutinin binding to specific sialic acid-bearing cellular proteins. ./. Immunol. (1995) 154:3952–3960.
  • KIDO H, BEPPU Y, IMAMURA Y et al.: The human mucus protease inhibitor and its mutants are novel defensive compounds against infection with influenza A and Sendai viruses. Biopoboners (1999) 51:79–86.
  • SAUTER NK, GLICK GD, CROWTHER RL et al.: Crystallographic detection of a second ligand binding site in influenza virus hemagglutinin. Biochemistry (1992) 89:324–328.
  • GLICK GD, TOOGOOD PL, WILEY DC, SKEHEL JJ, KNOWLES JR: Ligand recognition by influenza virus. I Biol. Chem. (1991) 266:23660–23669.
  • LANDERS J, CAO Z, LEE I et al.: Prevention of influenza pneumonitis by sialic acid-conjugated dendritic polymers. I /of Dis. (2002) 186:1222–1230.
  • GAMBARYAN A, TUZIKOV A, CHINAREV A, JUNEJA L, BOVIN N, MATROSOVICH M: Polymeric inhibitor of influenza virus attachment protects mice from experimental influenza infection. Antiviral Res. (2002) 55:201–205.
  • GUO C, SUN X, KANIE O et al.: An O-glycoside of sialic acid derivative that inhibits both hemagglutinin and sialidase activities of influenza viruses. Giycoibioiogy (2002) 12:183–190.
  • GARCIA-SASTRE A, DURBIN R, ZHENG H et al.: The role of interferon in influenza virus tissue tropism. J. Virol. (1998) 72:8550–8558.
  • WANG X, MING L, ZHENG H et al.: Influenza A virus NS1 protein prevents activation of NFkB and induction of alpha/beta interferon. J. Virol (2000) 74:11566–11573.
  • GEISS G, SALVATORE M, TUMPEY T et al.: Cellular transcription profiling in influenza A virus-infected lung epithelial cells: ther role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza. Five. Natl. Acad. Sci. USA. (2002) 99:10736–10741.
  • HAYNES L, MOOR D, KURT-JONES E, FINBERG R, ANDERSON L, TRIPP R: Involvement of Toll-like receptor 4 in innate immunity to Respiratory Syncitial Virus. J. Vim]. (2001) 75:10730–10737.
  • DIEBOLD S, KAISHO T, HEMMI H, AKIRA S, SOUSA CE: Innate antiviral responses by means of TLR7-mediated recognition of single stranded RNA. Schnce (2004) 303:1529–1531.
  • SEO S, WEBSTER R: Tumor necrosis factor alpha exerts powerful anti-influenza virus effects in lung epithelial cells. J. Virol. (2002) 76:1071–1076.
  • HUSSELL T, PENNYCOOK A, OPENSHAW P: Inhibition of tumor necrosis factor reduces the severityof virus-specific lung immunopathology. Eur. Immunol. (2001) 31:2566–2573.
  • SEO S, HOFFMAN E, WEBSTER R: Lethal H5N1 influenza viruses escape host anti-viral cytokine responses. Nat. Med. (2002) 8:950–954.
  • TRAVIS S, SINGH E WALSH M: Antimicrobial peptides and proteins in the innate defense of the airway surface. Curc °pia Immunol. (2001) 13:89–95.
  • DAHER K, SELSTED M, LEHRER R: Direct inactivation of viruses by human granulocyte defensins. Vim]. (1986) 60:1068–1074.
  • HILL C, YEE J, SELSTED M, EISENBERG D: Crystal structure of defensin HNP-3, and amphiphilic dimes: mechanisms of membrane permeabilization. Science (1991) 251:1481–1485.
  • YANG D, CHERTOV O, BYKOVSHAIA S et al: f3 defensins: linking innate and adaptive immunity through dendritic cells and T cell CCR6. Science (1999) 286:525–528.
  • MADSEN J, KLIEM A, TORNOE I, SKJOLT K, KOCH C, HOLMSKOV U: Localization of lung surfactant protein D on mucosal surfaces in human tissues. Immunol (2000) 164:5866–5870.
  • HARTSHORN KL, CROUCH EC, WHITE MR et al: Evidence for a protective role of pulmonary surfactant protein D (SP-D) against influenza A viruses. Clin. Invest. (1994) 94:311–319.
  • HARTSHORN K, WHITE M, VOELKER D, COBURN J, ZANER K, CROUCH E: Mechanism of binding of surfactant surfactant protein D to influenza A viruses: importance of binding to hemagglutinin to antiviral activity. Biochem. J. (2000) 351:449–458.
  • CROUCH E, HARTSHORN K, OFEK I: Collectins and pulmonary innate immunity. Immunol Rev (2000) 173:52–65.
  • READING P, MOREY L, CROUCH E, ANDERS E: Collectin-mediated antiviral host defense of the lung: evidence from influenza virus infection of mice. [ Vim]l (1997) 71:8204–8212.
  • TURNER M: Functional aspects of mannose binding protein. In: Collectins and innate immunity Sastry K, Ezekowitz R (Eds.), RG Landes, Austin, Texas (1996):73–97.
  • GARRED P, MADSEN H, BALSLEV U, PEDERSEN C, GERSTOFT J, SVEGAARD A: Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet (1997) 349:236–240.
  • READING P, ALLISON J, CROUCH E, ANDERS E: Increased susceptibility of diabetic mice to influenza virus infection: compromise of collectin-mediated host defense of the lung by glucose. J. Vim] (1998) 72:6884–6887.
  • LEVINE A, WHITSETT J, HARTSHORN K, KORFHAGEN T: Surfactant protein D enhances clearance of influenza A virus from the lung in vivo. Immunol (2001) 167:5868–5873.
  • LEVINE A, HARTSHORN K, ELLIOT J, WHITSETT J, KORFHAGEN T: Surfactant protein A modulates both innate and adaptive defense responses to pulmonary influenza A virus infection. Am. J. Physiol Lung Cell Mol Physiol (2001) 282:L563–L572.
  • KOCH A, MELBYE M, SORENSEN P et al.: Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood. IA/VIA (2001) 285:1316–1321.
  • POSTLE A, MANDER A, REID K et al: Deficient hydrophilic surfactant proteins A and D with normal surfactant phospholipid molecular species in cystic fibrosis. Am. J. Resp. Cell. Mol Biol. (1999) 20:90–98.
  • HICKLING T, MALHOTRA R, SIM R: Human surfactant protein A exists in several different oligomeric states: oligomer size distribution varies between patient groups. Mol Med. (1998) 4:266–275.
  • HONDA Y, TAKAHASHI H, KUROKI Y, AKINO T, ABE S: Decreased contents of surfactant proteins A and D in BAL fluids of Healthy smokers. Chest (1996) 109:1006–1009.
  • FLOROS J, LIN H, GARCIA A et al.: Surfactant protein marker alleles identify a subgroup of tuberculosis patients in a Mexican population. J. Infect. Dis. (2000) 182:1473–1478.
  • LAHTI M, LOFGREN J, MARTILLA T et al.: Surfactant protein D gene polymorphism associated with severe respiratory syncytial virus infection. Pediatr: Res. (2002) 51:696–699.
  • LETH-LARSEN R, GARRED P, JENSENIUS H et al.: A common polymorphism in the SFTPD gene influences assembly, function and concentraion of surfactant protein D. Immunol (2005) 174:1532–1538
  • HARTSHORN K, CHANG D, RUST K, WHITE M, HEUSER J, CROUCH E: Interactions of recombinant human pulmonary surfactant protein D and SPD multimers with influenza A. Am. J. Physiol (1996) 271:L753–L762.
  • HARTSHORN K, REID K, WHITE M, MORRIS S, JENSENIUS J, CROUCH E: Neutrophil deactivation by influenza A viruses: mechanisms of protection after viral opsonization with collectins and hemagglutination-inhibiting antibodies. Blood (1996) 87:3450–3461.
  • HARTSHORN K, CROUCH E, WHITE M et al.: Pulmonary surfactant proteins A and D enhance neutrophil uptake of bacteria. Amer J. Physiol (1998) 274:L958–L969.
  • WU H, KUZMENKO A, WAN S et al: Surfactant proteins A and D inhibit the growth of Gram-negative bacteria by increasing membrane permeability. Clin. Invest. (2003) 111:1589–1602.
  • HICKLING T, BRIGHT H, WING K et al.: A recombinant trimeric surfactant protein D carbohydrate recognition domain inhibits respiratory synctitial virus infection in vitro and in vivo. Eur. I Immunol (1999) 29:3478–3484.
  • HARROD K, TRAPNELL B, OTAKE K, KORFHAGEN T, WHITSETT J: SP-A enhances viral clearance and inhibits inflammation after pulmonary adenoviral infection. Amer" Physiol (1999) 277:580–588.
  • WRIGHT J: Immunomodulatory functions of surfactant. Physio. Rev (1997) 77:931–962.
  • BORRON P, MCCORMACK F, ELHALWAGI B et al: Surfactant protein A inhibits T cell proliferation via its collagen-like tail and a 210-kDa receptor. Am. J. Physiol (1998) 275:L679–L686.
  • BRINKER K, MARTIN E, BORRON P et al.: Surfactant protein D enhances bacterial antigen presentation by bone-marrow derived dendritic cells. Am. J. Physiol (2001) 281:L1453–L1463.
  • VANDIVIER R, OGDEN C, FADOK V et al.: Role fo surfactant proteins A, D and Clq in the clearance of apoptotic cells in vivo and in vitro: calreticulin and CD91 as a common receptor complex. J. Immunol (2002) 169:3978–3986.
  • CLARK H, PALANIYAR N, STRONG P, EDMONDSON J, HAWGOOD S, REID K: Surfactant protein D reduces alveolar macrophage apoptosis in vivo. Immunol (2002) 169:2892–2899.
  • HARTSHORN K, SASTRY K, CHANG D, WHITE M, CROUCH E: Enhanced antinfluenza activity of a recombinant pulmonary surfactant protein D and serum conglutinin fusion protein. Am. .1 Physiol. (2000) 278:L90–L98.
  • WHITE M, CROUCH E, CHANG D et al.: Enhanced antiviral and opsonic activity of a human mannose binding lectin and surfactant protein D fusion protein. ". Immunol. (2000) 165:2108–2155.
  • HARTSHORN KL, SASTRY K, BROWN D et al: Conglutinin acts as an opsonin for influenza A viruses. Immunol. (1993) 151:1–9.
  • HARTSHORN K, HOLMSKOV U, WHITE M, MESCHI J, CROUCH E: Distinctive antiviral properties of collectin-43 (CL-43). Biochem. (2002) 366:87–96.
  • ZHANG L, HARTSHORN K, CROUCH E, IKEGAMI M, WHITSETT J: Complementation of pulmonary abnormalities in SP-D (-/-) mice with an SP-D/Conglutinin fusion protein. J. Biol. Chem. (2002) 277:22453–22459.
  • STRONG P, REID K, CLARK H: Intranasal delivery of a truncated recombinant human SP-D is effective at down-regulating allergic hypersensitivity in mice sensitized to allergens of aspergillus fumigatus. Chi]. Exp. Immunol. (2002) 130:19–24.
  • TACKENP, HARTSHORN K, WHITE M et al.: Effective targeting of pathogens to neutrophils via chimeric surfactant protein D/anti-CD89 protein. J. Immunol. (2004) 172:4934–4940.
  • HARTLEY CA, JACKSON DC, ANDERS ME: Two distinct serum mannose-binding lectins functions as B inhibitors of influenza virus: identification of bovine serum B inhibitor as conglutinin. Virol. (1992) 66:4358–4363.
  • HARTLEY C, READING P, WARD A, ANDERS E: Changes in hemagglutinin molecule of influenza type A (H3N2) virus associated with increased virulence in mice. Arch. Virol. (1997) 142:75–88.
  • HARTSHORN K, WHITE M, SHEPHERD V, REID K, JENSENIUS J, CROUCH E: Mechanisms of anti-influenza activity of pulmonary surfactant proteins A and D: comparison with other collectins. Am. I Physiol. (1997) 273:L1156–L1166.
  • HARTSHORN KL, WHITE MR, MOGUES T, LIGTENBERG T, CROUCH E, HOLMSKOV U: Lung and salivary scavenger receptor glycoprotein-340 contribute to the host defense against influenza A viruses. Am. I Physiol. Lung Cell Mol. Physiol. (2003) 285:L1066–L1076.
  • HARTSHORN K: Etiology of Bacterial Superinfections complicating influenza viral infection. In: Options for the Control of Influenza. Brown L, Hampson A, Webster R (Eds.), Elsevier Science, Amsterdam (1996):499–508.
  • ABRAMSON JS, GIEBINK GS, QUIE PG: Influenza A virus-induced polymorphonuclear leukocyte dysfunction in the pathogenesis of experimental pneumococcal otitis media. Infect. Immun. (1982) 36:289–296.
  • TASHIRO M, KLENK H, ROTT R: Inhibitory effect of a protease inhibitor, leupeptin, on the development of influenza pneumonia, mediated by concommitant bacterial Gen. Virol. (1987) 68:2039–2041.
  • MCCULLERS JA, BARTMESS KC: Role of Neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae. Inf. Dis. (2003) 187:1000–1009.
  • MANDELBOIM O, LIEBERMAN N, LEV M et al: Recognition of haemagglutinins of virus-infected cells by NKp46 activates lysis by NK cells. Nature (2001) 409:1055–1060.
  • ARNON TI, ACHDOUT H, LIEBERMAN N et al: The mechanisms controlling the recognition of tumor- and virus-infected cells by NKp46. Blood (2004) 103:664–672.
  • LI W, LI H, LU R et al.: Interferon antagonist proteins of influenza and vaccinia viruses are suppressors of RNA silencing. Proc. Nati Acad. Sci. USA. (2004) 101:1350–1355.
  • TOMPKINS SM, LO CY, TUMPEY TM, EPSTEIN SL: Protection against lethal influenza virus challenge by RNA interference in vivo. Proc. Natl. Acad. Sci. USA (2004) 101:8682–8686.
  • GE Q, FILIP L, BAI A, NGUYEN T, EISEN HN, CHEN J: Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc. Natl. Acad. Sci. USA (2004) 101:8676–8681.
  • GE Q, EISEN HN, CHEN J: Use of sirnas to prevent and treat influenza virus infection. Virus Res. (2004)102:37–42.
  • TUMPEY TM, LU X, MORKEN T, ZAKI SR, KATZ JM: Depletion of lymphocytes and diminished cytokine production in mice infected with a highly virulent influenza A (H5N1) virus isolated from human. J. Virol. (2000) 74:6105–6116.
  • AKAIKE T, NOGUCHI Y, IJIRI S et al.: Pathogenesis of influenza virus-induced pneumonia: involvement of both nitric oxide and oxygen radicals. Proc. Nati Acad. Sci. USA (1996) 93:2448–2453.
  • CHOI A, KNOBIL K, OTTERBEIN S, EASTMAN D, JACOBY D: Oxidant stress responses in influenza virus pneumona: gene expression and transcription factor activation. Am. J. Physiol. (1996) 271:L383–L391.
  • ENGELICH G, WHITE M, HARTSHORN K: Neutrophil survival is markedly reduced by incubation with influenza virus and Streptococcus pneumoniae: role of respiratory burst. Leuk. Biol. (2001) 69:50–56.
  • ARNDT U, WENNEMUTH G, BARTH P et al.: Release of macrophage migration factor and CXCL8/interleukin-8 from lung epithelial cells rendered necrotic by influenza A virus infection. I Virol. (2002) 76:9298–9306.
  • SAKAI S, KAWAMATA H, MANTANI N et al.: Therapeutic effect of anti-macrophage inflammatory protein 2 antibody in influenza virus-induced pneumonia in mice. I Virol. (2000) 74:2472–2476.
  • FUJISAWA H, TSURU S, TANIGUCHI M, ZINNAKA Y, NOMOTO K: Protective mechanisms against pulmonary infection with influenza virus. I. Relative contribution of polymorphonuclear leukocytes ond of alveolar mactrophages to protection during the early phase of intranasal infection. Gen. Virol. (1987) 68:425–432.
  • DAWSON TC, BECK MA, KUZIEL WA, HENDERSON F, MAEDA N: Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus. Am. I Patna (2000) 156:1951–9.
  • DAHL M, DABBAGH K, LIGGITT D, KIM S, LEWIS D: Viral-induced T helper 1 responses enhance allergic disease by effects on lung dendritic cells. Nat. Immune]. (2004) 5:337–343.
  • TSITOURA D, KIM S, DABBAGH K, BERRY G, LEWIS D, UMETSU D: Respiratory infection with influenza A virus interferes with the induction of tolerance to aeroallergens. Immune]. (2000) 165:3484–3491.
  • ATOCHINA EN, BEERS ME TOMER Y et al.: Attenuated allergic airway hyperresponsiveness in C57BL/6 mice is associated with enhanced surfactant protein (SP)-D production following allergic sensitization. Respiratory Research (2003) 4:1–12.
  • UNGCHUSAK K, AUEWARAKUL P, DOWELL SF et al: Probably person-to-person transmission of avian influenza (H5N1). N Eng. J. Med. (2005) 352:330–40.

Website

  • http://www.fda.gov/cder/drug/advisory/influe nza.htm 2000 Food and Drug Administration public health advisory: safe and appropriate use of influenza drugs (2000).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.